Cargando…

Intra‐individual variation of circulating tumour DNA in lung cancer patients

Circulating tumour DNA (ctDNA) has been increasingly incorporated into the treatment of cancer patients. ctDNA is generally accepted as a powerful diagnostic tool, whereas the utility of ctDNA to monitor disease activity needs to be fully validated. Central to this challenge is the question of wheth...

Descripción completa

Detalles Bibliográficos
Autores principales: Hojbjerg, Johanne A., Madsen, Anne T., Schmidt, Hjordis H., Sorensen, Steffen F., Stougaard, Magnus, Meldgaard, Peter, Sorensen, Boe S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763781/
https://www.ncbi.nlm.nih.gov/pubmed/31306545
http://dx.doi.org/10.1002/1878-0261.12546
_version_ 1783454271915687936
author Hojbjerg, Johanne A.
Madsen, Anne T.
Schmidt, Hjordis H.
Sorensen, Steffen F.
Stougaard, Magnus
Meldgaard, Peter
Sorensen, Boe S.
author_facet Hojbjerg, Johanne A.
Madsen, Anne T.
Schmidt, Hjordis H.
Sorensen, Steffen F.
Stougaard, Magnus
Meldgaard, Peter
Sorensen, Boe S.
author_sort Hojbjerg, Johanne A.
collection PubMed
description Circulating tumour DNA (ctDNA) has been increasingly incorporated into the treatment of cancer patients. ctDNA is generally accepted as a powerful diagnostic tool, whereas the utility of ctDNA to monitor disease activity needs to be fully validated. Central to this challenge is the question of whether changes in longitudinal ctDNA measurements reflect disease activity or merely biological variation. Thus, the aim of this study was to explore the intra‐individual biological variation of ctDNA in lung cancer patients. We identified tumour‐specific mutations using next‐generation sequencing. Day‐to‐day and hour‐to‐hour variations in plasma concentrations of the mutant allele and wild‐type cell‐free DNA (cfDNA) were determined using digital PCR. The levels of the mutant alleles varied by as much as 53% from day to day and 27% from hour to hour. cfDNA varied up to 19% from day to day and up to 56% from hour to hour, as determined using digital PCR. Variations were independent of the concentration. Both mutant allele concentrations and wild‐type cfDNA concentrations showed considerable intra‐individual variation in lung cancer patients with nonprogressive disease. This pronounced biological variation of the circulating DNA should be investigated further to determine whether ctDNA can be used for monitoring cancer activity.
format Online
Article
Text
id pubmed-6763781
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-67637812019-10-01 Intra‐individual variation of circulating tumour DNA in lung cancer patients Hojbjerg, Johanne A. Madsen, Anne T. Schmidt, Hjordis H. Sorensen, Steffen F. Stougaard, Magnus Meldgaard, Peter Sorensen, Boe S. Mol Oncol Research Articles Circulating tumour DNA (ctDNA) has been increasingly incorporated into the treatment of cancer patients. ctDNA is generally accepted as a powerful diagnostic tool, whereas the utility of ctDNA to monitor disease activity needs to be fully validated. Central to this challenge is the question of whether changes in longitudinal ctDNA measurements reflect disease activity or merely biological variation. Thus, the aim of this study was to explore the intra‐individual biological variation of ctDNA in lung cancer patients. We identified tumour‐specific mutations using next‐generation sequencing. Day‐to‐day and hour‐to‐hour variations in plasma concentrations of the mutant allele and wild‐type cell‐free DNA (cfDNA) were determined using digital PCR. The levels of the mutant alleles varied by as much as 53% from day to day and 27% from hour to hour. cfDNA varied up to 19% from day to day and up to 56% from hour to hour, as determined using digital PCR. Variations were independent of the concentration. Both mutant allele concentrations and wild‐type cfDNA concentrations showed considerable intra‐individual variation in lung cancer patients with nonprogressive disease. This pronounced biological variation of the circulating DNA should be investigated further to determine whether ctDNA can be used for monitoring cancer activity. John Wiley and Sons Inc. 2019-08-16 2019-10 /pmc/articles/PMC6763781/ /pubmed/31306545 http://dx.doi.org/10.1002/1878-0261.12546 Text en © 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Hojbjerg, Johanne A.
Madsen, Anne T.
Schmidt, Hjordis H.
Sorensen, Steffen F.
Stougaard, Magnus
Meldgaard, Peter
Sorensen, Boe S.
Intra‐individual variation of circulating tumour DNA in lung cancer patients
title Intra‐individual variation of circulating tumour DNA in lung cancer patients
title_full Intra‐individual variation of circulating tumour DNA in lung cancer patients
title_fullStr Intra‐individual variation of circulating tumour DNA in lung cancer patients
title_full_unstemmed Intra‐individual variation of circulating tumour DNA in lung cancer patients
title_short Intra‐individual variation of circulating tumour DNA in lung cancer patients
title_sort intra‐individual variation of circulating tumour dna in lung cancer patients
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763781/
https://www.ncbi.nlm.nih.gov/pubmed/31306545
http://dx.doi.org/10.1002/1878-0261.12546
work_keys_str_mv AT hojbjergjohannea intraindividualvariationofcirculatingtumourdnainlungcancerpatients
AT madsenannet intraindividualvariationofcirculatingtumourdnainlungcancerpatients
AT schmidthjordish intraindividualvariationofcirculatingtumourdnainlungcancerpatients
AT sorensensteffenf intraindividualvariationofcirculatingtumourdnainlungcancerpatients
AT stougaardmagnus intraindividualvariationofcirculatingtumourdnainlungcancerpatients
AT meldgaardpeter intraindividualvariationofcirculatingtumourdnainlungcancerpatients
AT sorensenboes intraindividualvariationofcirculatingtumourdnainlungcancerpatients